• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tandem Diabetes Care Appoints Mark Novara as EVP and Chief Commercial Officer

    11/1/23 4:06:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care
    Get the next $TNDM alert in real time by email

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Mark Novara as Executive Vice President and Chief Commercial Officer, effective November 13, 2023. Mr. Novara comes to Tandem with extensive global healthcare experience, having served in the diabetes, medical technology, and life sciences industries for nearly 25 years.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231101343981/en/

    Mark Novara (Photo: Business Wire)

    Mark Novara (Photo: Business Wire)

    "Mark is a strategic, global leader with a successful track record of driving above market business growth, while building scalable commercial operations and delivering best-in-class customer experience," said John Sheridan, president and CEO. "We welcome Mark to our leadership team at this exciting stage in Tandem's evolution, as we prepare to expand our family of innovative technologies and execute on our shared vision to improve the lives of people with diabetes."

    "I was drawn to Tandem's mission-driven commitment to innovation and their customer-centric culture," said Mr. Novara. "Tandem has a strong portfolio powered by Control-IQ technology that provides compelling clinical results for people living with diabetes. I am excited to be joining Tandem at this pivotal time and look forward to working closely with the team to build on its strong foundation through new product launches, commercial excellence and global expansion."

    Mr. Novara joins Tandem Diabetes Care from McKinsey & Company, where he served as Senior Advisor in the Medical Technology/Life Science practice since February 2023. Before that time, Mr. Novara held executive positions at Becton Dickinson for more than a decade, most recently serving as Worldwide Vice President and General Manager in Medication Delivery Solutions, as Senior Vice President, Global Strategic Marketing for the Medical and Life Sciences Segments, and as Worldwide Vice President and General Manager in Diabetes Care. He also held leadership positions with Roche and Sanofi-Aventis. Mr. Novara received a BS in Biology from Villanova University, and a Masters in Healthcare Management from Columbia University.

    About Tandem Diabetes Care, Inc.

    Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The company's human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 pump with Control-IQ technology. For more information, visit tandemdiabetes.com.

    Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2 and #TandemDiabetes.

    Follow Tandem Diabetes Care on Facebook at facebook.com/TandemDiabetes.

    Follow Tandem Diabetes Care on LinkedIn at linkedin.com/company/tandemdiabetes.

    © 2023 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. All third-party marks are the property of their respective owners.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231101343981/en/

    Get the next $TNDM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TNDM

    DatePrice TargetRatingAnalyst
    6/16/2025$24.00Hold
    Truist
    4/10/2025$20.00Neutral
    Mizuho
    3/5/2025$45.00 → $22.00Overweight → Equal-Weight
    Morgan Stanley
    3/4/2025$35.00 → $24.00Buy → Neutral
    Citigroup
    3/3/2025$38.00 → $22.00Overweight → Equal Weight
    Wells Fargo
    2/28/2025$35.00 → $25.00Outperform → Mkt Perform
    Bernstein
    12/2/2024$45.00Equal-Weight → Overweight
    Morgan Stanley
    11/6/2024$42.00Outperform
    Bernstein
    More analyst ratings

    $TNDM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technology Officer Carpenter Rick converted options into 406 shares and covered exercise/tax liability with 207 shares, increasing direct ownership by 0.95% to 21,219 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      6/18/25 4:08:32 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • EVP & CHIEF COMMERCIAL OFFICER Novara Mark David converted options into 7,414 shares and covered exercise/tax liability with 3,846 shares, increasing direct ownership by 14% to 28,763 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      6/18/25 4:08:21 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Director Cha Myoungil converted options into 1,749 shares, increasing direct ownership by 15% to 13,699 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      6/18/25 4:08:10 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • February 28, 2025 - FDA Roundup: February 28, 2025

      For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

      2/28/25 5:00:47 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • November 7, 2023 - FDA Roundup: November 7, 2023

      For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse

      11/7/23 3:38:18 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Chief Operating Officer Kyrillos Jean-Claude bought $190,966 worth of shares (10,538 units at $18.12) (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      3/11/25 6:06:01 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • EVP & CHIEF COMMERCIAL OFFICER Novara Mark David bought $12,364 worth of shares (532 units at $23.24) (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      11/19/24 5:23:14 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Allen Dick bought $94,778 worth of shares (5,000 units at $18.96), increasing direct ownership by 33% to 19,962 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      11/29/23 4:10:39 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Leadership Updates

    Live Leadership Updates

    See more
    • Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620151195/en/Jean-Claude "JC" Kyrillos (Photo: Business Wire) "JC brings deep experience in healthcare and a great balance of technical, operational, and leadership skills from multipl

      6/20/24 9:00:00 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care, Inc investors: Please contact the Portnoy Law Firm to recover your losses; November 2, 2023 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio

      11/7/23 3:47:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care, Inc investors: Please contact the Portnoy Law Firm to recover your losses; November 2, 2023 deadline.

      Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' opti

      11/1/23 8:03:30 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Financials

    Live finance-specific insights

    See more
    • Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2025 results after the financial markets close on Wednesday, August 6, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI0d

      7/1/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces First Quarter 2025 Financial Results

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2025. First Quarter 2025 Highlights, Financial Results Compared to First Quarter 2024 Achieved record first quarter sales with worldwide growth of 22% Increased pump sales in the United States by 19% on a GAAP basis and 17% on a non-GAAP(1) basis, on strong shipment growth and average selling price improvement Delivered 5 point adjusted EBITDA(1) margin increase Approximately 30% of U.S. lives now covered through pharmacy benefits for Tandem Mobi Benefits of Control-IQ Technology were featured for a fourth time i

      4/30/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2025 results after the financial markets close on Wednesday, April 30, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI72222

      4/3/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Tandem Diabetes Care with a new price target

      Truist initiated coverage of Tandem Diabetes Care with a rating of Hold and set a new price target of $24.00

      6/16/25 7:53:54 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Mizuho initiated coverage on Tandem Diabetes Care with a new price target

      Mizuho initiated coverage of Tandem Diabetes Care with a rating of Neutral and set a new price target of $20.00

      4/10/25 12:43:51 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Tandem Diabetes Care from Overweight to Equal-Weight and set a new price target of $22.00 from $45.00 previously

      3/5/25 7:47:44 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    SEC Filings

    See more
    • SEC Form SD filed by Tandem Diabetes Care Inc.

      SD - TANDEM DIABETES CARE INC (0001438133) (Filer)

      5/29/25 4:42:26 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders

      8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

      5/23/25 4:21:45 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Inc. filed SEC Form 8-K: Other Events

      8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

      5/12/25 5:16:49 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2025 results after the financial markets close on Wednesday, August 6, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI0d

      7/1/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott's FreeStyle Libre® 3 Plus Sensor in the United States

      Tandem continues to build its technology ecosystem to expand choice and personalization for people living with diabetes Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor. The Company has initiated an early access program in the United States (U.S.), and intends to scale availability in the second half of 2025. "Diabetes management is not one-size-fits-all and it is critical for people living with diabetes to be able to personalize their

      6/20/25 8:30:00 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes. The Abbott sensor, currently under development, will combine glucose and ketone sensing technology that aims to help people living with diabetes detect early ketone rise to avoid life-threatening diabetic ketoacidosis. "Integrating our advanced insulin delivery systems with Abbott's future glucose-ketone sensor has the potential to help

      6/10/25 8:30:00 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    $TNDM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

      SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

      11/14/24 4:15:44 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

      SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

      9/9/24 10:40:31 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Tandem Diabetes Care Inc.

      SC 13G - TANDEM DIABETES CARE INC (0001438133) (Subject)

      2/14/24 7:37:31 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care